On the way to increasing its export potential, the St. Petersburg Research Institute of Vaccines and Serums of the FMBA of Russia, in June 2018, successfully passed an audit with the specialists of the Food and Drug Administration of the Islamic Republic of Iran for conformity of antigen production required for influenza vaccine.
The institute received a certificate confirming the full conformity of the production of SPbRIVS with the GMP requirements in August of this year.
It is worth reminding that in July 2018, a partner of SPbRIIVS, NPO Petrovax Pharm company, received Registration Certificate No. ЛП-004951 of 23.07.2018 on the inactivated quadrivalent subunit-adjuvanted vaccine for the prevention of influenza – Grippol® Quadrivalent. The vaccine will be produced in Russia using full-cycle technology, starting with the stage of manufacturing substances, including antigens, according to GMP standards in disposable syringes without preservatives. In this project, SPbRIIVS acts as a supplier of influenza vaccine antigen.